Second week at 12mg of reta!
Appetite supression is really mild I can still eat 2000kcal (on a 3000kcal maintenance).
HR is almost the same. Skin sensations are really down but it weirdly depends on the day.
Here a 1 month difference. A few kilos of fat to lose and I’ll be good. I don’t plan to lower the dose, I want to downsize a bit (I was up to 92kg for 1m72, cardio was getting harder and moving was difficult for some movements like putting my socks…
How is the sleep apnea going?
The CPAP is a game changer, I no longer fall asleep everywhere and I feel rested when I wake up.
I average 9h of sleep.
Last time the technician was here the count of sleep apnea has been divided by 65, I was doing 2 events an hour instead of 128.
BP and HR and down.
Nice. Better to have it under control but hopefully you can get rid of the sleep apnea entirely and not need the machine. Machine drove me crazy.
My whole X feed is discussing the Retatrutide phase 3 results. Seems to be what everyone is talking about right now.
I wonder if the other metabolic/anti inflammation etc health affects are just as dose dependent… thats why I was aiming to get up there in dosage
Apparently there are tests to measure glp-1 in plasma which I may need. Aside from being an ectomorph, I think a possible reason I’m responding so well in terms of weight loss/side effects to a lower dosage is because of the other supplements I’m taking that either are additive or synergistic to the process. Not only the copies glycine I take, but apparently Telmisartan (and I take 80 mg) acts synergistic with it and who knows what else in a persons lengthy stack could influence the process
I suspect not, if someone responds very well to the drug. But metabolic benefits are things you can easily measure with blood tests to validate your hypothesis in your specific case.
Both increased RHR but not in a concerning way:
Tirz at 14mg/week - RHR up 4-5 from base
Reta at 12mg/week - RHR up 6-8 from base.
Base: 61 - Tirz: 65 - Reta: 69
I believe these tests for specific blood serum GLP or similar are proprietary to EL and Novo.
But the end goals are different and include biomarkers you can test:
Metabolic Health & Inflammation Panel
| Marker Category | Common Name | Exact Labcorp Test Name | Labcorp Test Code |
|---|---|---|---|
| Blood Sugar & Insulin | Fasting Glucose | Glucose, Serum (or as part of a Comprehensive Metabolic Panel) | 001032 (or 001400) |
| Blood Sugar & Insulin | Hemoglobin A1c | Hemoglobin (Hb) A1c | 001453 |
| Blood Sugar & Insulin | Fasting Insulin | Insulin | 004333 |
| Lipids & Cardiovascular | Standard Lipids | Lipid Panel | 303756 |
| Lipids & Cardiovascular | Apolipoprotein B | Lipid Panel with Apolipoprotein B (ApoB) | 123544 |
| Inflammation | hs-CRP | C-Reactive Protein (CRP), High Sensitivity (Cardiac Risk Assessment) | 120766 |
| Inflammation | Homocysteine | Homocyst(e)ine | 706994 |
And if bothering to test those, consider also testing common markers with valuable info:
Core Companion Panel Additions
| Marker Category | Common Name | Exact Labcorp Test Name | Labcorp Test Code |
|---|---|---|---|
| Foundational Health | CBC with Diff | CBC With Differential/Platelet | 005009 |
| Foundational Health | CMP | Comprehensive Metabolic Panel (14) | 001400 |
| Metabolic Control | TSH (Thyroid) | Thyroid-stimulating Hormone (TSH) | 004259 |
| Inflammation / Storage | Ferritin | Ferritin | 004598 |
| Metabolic / Gout Risk | Uric Acid | Uric Acid | 001057 |
| Hormone / Immune | Vitamin D | Vitamin D, 25-Hydroxy | 081950 |
New triple agonist GLP1 hitting the same things but likely different ratio of what it is hitting. I suspect more glucagon.
Novo Nordisk’s CEO believes its triple agonist UBT251 could ultimately outperform Eli Lilly’s retatrutide, though the evidence is still early. Retatrutide is already in late-stage trials and has shown about 28–30% weight loss over 1.5–2 years, which analysts describe as “unprecedented,” but with some tolerability concerns. UBT251 is still in phase II with about 20% weight loss at 24 weeks in early data. At present, retatrutide has much stronger clinical backing, while UBT251 is a promising but unproven challenger.